Gilead picks up dropped Novartis antiviral programs

Gilead in-licensed from Novartis three preclinical antiviral programs that will help build out its preclinical pipeline in indications outside of its historical focus.

Under the deal, Gilead Sciences Inc. (NASDAQ:GILD) receives exclusive, worldwide rights from Novartis AG (NYSE:NVS; SIX:NOVN) to small molecules against three undisclosed targets to treat rhinovirus, influenza and herpes virus...